Anumana’s ECG-AI LEF algorithm uses routine 12-lead ECG data to identify left ventricular ejection fraction. Credit: sasirin pamai / Shutterstock.

US-based health technology company Anumana has partnered with AliveCor for the development of its AI algorithms intended for the early identification of cardiac diseases.

The collaboration will initially integrate Anumana’s ECG-AI LEF algorithm into AliveCor’s Kardia electrocardiogram (ECG) devices.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

AliveCor recently introduced the Kardia 12L ECG system for healthcare professionals.

A handheld, AI-powered 12-lead resting ECG system, Kardia 12L features a ‘unique’ single-cable design that simplifies lead placement, allowing even those with limited ECG experience to obtain accurate recordings quickly.

This system is set to benefit from Anumana’s ECG-AI LEF algorithm, which is approved by the US Food and Drug Administration (FDA) and uses routine 12-lead ECG data to identify left ventricular ejection fraction (LEF), a key indicator of heart failure that is often underdiagnosed.

AliveCor chief business officer Sanjay Voleti said: “AliveCor is already at the forefront of AI in cardiology, transforming the industry with clinically validated solutions that disrupt traditional care pathways to create a more connected, holistic cardiac health ecosystem – like the recently FDA-cleared Kardia 12L ECG System.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This collaboration with Anumana will further strengthen our leadership in AI by expanding our solutions’ ability to facilitate more personalised and timely care across diverse healthcare settings.”

Founded by nference in partnership with Mayo Clinic, Anumana is an AI-driven health technology company that focuses on transforming ECG-AI technology into a practical tool for clinicians.

Anumana chief business officer David McMullin said: “Together with AliveCor, we are reshaping the future of cardiac care by unlocking new possibilities for early detection and intervention.

“This collaboration demonstrates Anumana’s commitment to harnessing the potential of AI to expand the utility of ECG technology, making traditional diagnostic tools more powerful for patients and clinicians.”

AliveCor is a medical device company specialising in AI-enabled ECG sensor technologies.

In June 2023, the ECG-AI algorithm received breakthrough device designation (BDD) from the FDA.